title: High survival rate in infant acute leukemia treated with early high-dose chemotherapy and stem-cell support. Groupo Español de Trasplante de Médula Osea en Niños.
abstract: OBJECTIVE
  Infants with acute leukemia have a poor prognosis when treated with conventional chemotherapy. It is still unknown if stem-cell transplantation (SCT) can improve the outcome of these patients. In the present study, we review our experience with SCT in infant acute leukemia to clarify this issue.
  
  
  METHODS
  We report the results of 26 infants who were submitted to a SCT for acute leukemia. There were 15 cases of acute myeloid leukemia and 10 cases of acute lymphoid leukemia. One patient had a bilineal leukemia. Twenty-two patients were in their first complete response (CR1), three were in their second CR, and one was in relapse. Eight patients were submitted to allogeneic SCT, and 18 underwent autologous SCT.
  
  
  RESULTS
  With a median follow-up of 67 months, the 5-year overall survival and disease-free survival (DFS) are 64% (SE = 9%) and 63% (SE = 10%), respectively. Autologous and allogeneic SCT offered similar outcome. There was not any transplant-related mortality, and all deaths were caused by relapse in the first 6 months after SCT. In multivariate analysis, the single factor associated with better DFS was an interval between CR1 and SCT of less than 4 months (P: <.025).
  
  
  CONCLUSIONS
  SCT is a valid option in the treatment of infant acute leukemia, and it may overcome the high risk of relapse with conventional chemotherapy showing very reduced toxicity. This study suggests that SCT should be performed in CR1 in the early phase of the disease.
authors.affiliation: Servicio de Hematología, Hospital Universitario Marqués de Valdecilla, Santander, Spain. fernandomarco@hotmail.com
authors.forename: F
authors.initials: F
authors.lastname: Marco
authors.forename: E
authors.initials: E
authors.lastname: Bureo
authors.forename: J J
authors.initials: JJ
authors.lastname: Ortega
authors.forename: I
authors.initials: I
authors.lastname: Badell
authors.forename: A
authors.initials: A
authors.lastname: Verdaguer
authors.forename: A
authors.initials: A
authors.lastname: Martínez
authors.forename: A
authors.initials: A
authors.lastname: Muñoz
authors.forename: L
authors.initials: L
authors.lastname: Madero
authors.forename: T
authors.initials: T
authors.lastname: Olivé
authors.forename: J
authors.initials: J
authors.lastname: Cubells
authors.forename: V
authors.initials: V
authors.lastname: Castel
authors.forename: A
authors.initials: A
authors.lastname: Sastre
authors.forename: M S
authors.initials: MS
authors.lastname: Maldonado
authors.forename: M A
authors.initials: MA
authors.lastname: Díaz
mesh_terms: D000208:Acute Disease; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000628:therapy*; D016015:Logistic Models; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000628:therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome